BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 24897388)

  • 21. Cyanidin Curtails Renal Cell Carcinoma Tumorigenesis.
    Liu X; Zhang D; Hao Y; Liu Q; Wu Y; Liu X; Luo J; Zhou T; Sun B; Luo X; Xu J; Wang Q; Yang Z; Li L
    Cell Physiol Biochem; 2018; 46(6):2517-2531. PubMed ID: 29742507
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Suppression of renal cell carcinoma growth in vivo by forced expression of vascular endothelial growth inhibitor.
    Zhang N; Wu P; Shayiremu D; Wu L; Shan H; Ye L; Zhao X; Cai J; Jiang WG; Gong K; Yang Y
    Int J Oncol; 2013 May; 42(5):1664-73. PubMed ID: 23545578
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma.
    Riesenberg R; Weiler C; Spring O; Eder M; Buchner A; Popp T; Castro M; Kammerer R; Takikawa O; Hatz RA; Stief CG; Hofstetter A; Zimmermann W
    Clin Cancer Res; 2007 Dec; 13(23):6993-7002. PubMed ID: 18056175
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protein tyrosine phosphatase nonreceptor type 12 suppresses the proliferation of renal cell carcinoma by inhibiting the activity of the PI3K/mTOR pathway.
    Piao YR; Jin ZH
    J BUON; 2015; 20(5):1258-66. PubMed ID: 26537073
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 5-Lipoxygenase inhibitors attenuate growth of human renal cell carcinoma and induce apoptosis through arachidonic acid pathway.
    Matsuyama M; Yoshimura R; Mitsuhashi M; Tsuchida K; Takemoto Y; Kawahito Y; Sano H; Nakatani T
    Oncol Rep; 2005 Jul; 14(1):73-9. PubMed ID: 15944770
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Significance of Fas expression alteration during tumor progression of renal cell carcinoma.
    Sejima T; Miyagawa I
    Int J Urol; 2006 Mar; 13(3):257-64. PubMed ID: 16643620
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cannabinoid receptor 2 as a novel target for promotion of renal cell carcinoma prognosis and progression.
    Wang J; Xu Y; Zhu L; Zou Y; Kong W; Dong B; Huang J; Chen Y; Xue W; Huang Y; Zhang J
    J Cancer Res Clin Oncol; 2018 Jan; 144(1):39-52. PubMed ID: 28993942
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Upregulated expression of eIF3C is associated with malignant behavior in renal cell carcinoma.
    Fan M; Wang K; Wei X; Yao H; Chen Z; He X
    Int J Oncol; 2019 Dec; 55(6):1385-1395. PubMed ID: 31638200
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metastin inhibits migration and invasion of renal cell carcinoma with overexpression of metastin receptor.
    Shoji S; Tang XY; Umemura S; Itoh J; Takekoshi S; Shima M; Usui Y; Nagata Y; Uchida T; Osamura RY; Terachi T
    Eur Urol; 2009 Feb; 55(2):441-9. PubMed ID: 18395325
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TRIM59 is a key regulator of growth and migration inrenal cell carcinoma.
    Hu SH; Zhao MJ; Wang WX; Xu CW; Wang GD
    Cell Mol Biol (Noisy-le-grand); 2017 May; 63(5):68-74. PubMed ID: 28719348
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Silencing of CXCR4 by RNA interference inhibits cell growth and metastasis in human renal cancer cells.
    Wang L; Huang T; Chen W; Gao X; Zhou T; Wu Z; Sun Y
    Oncol Rep; 2012 Dec; 28(6):2043-8. PubMed ID: 22972438
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The enhancer of zeste homolog 2 gene contributes to cell proliferation and apoptosis resistance in renal cell carcinoma cells.
    Wagener N; Holland D; Bulkescher J; Crnković-Mertens I; Hoppe-Seyler K; Zentgraf H; Pritsch M; Buse S; Pfitzenmaier J; Haferkamp A; Hohenfellner M; Hoppe-Seyler F
    Int J Cancer; 2008 Oct; 123(7):1545-50. PubMed ID: 18623083
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Estrogen receptor-binding fragment-associated antigen 9 is a tumor-promoting and prognostic factor for renal cell carcinoma.
    Ogushi T; Takahashi S; Takeuchi T; Urano T; Horie-Inoue K; Kumagai J; Kitamura T; Ouchi Y; Muramatsu M; Inoue S
    Cancer Res; 2005 May; 65(9):3700-6. PubMed ID: 15867365
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RCCRT1 is correlated with prognosis and promotes cell migration and invasion in renal cell carcinoma.
    Song S; Wu Z; Wang C; Liu B; Ye X; Chen J; Yang Q; Ye H; Xu B; Wang L
    Urology; 2014 Sep; 84(3):730.e1-7. PubMed ID: 25168566
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Wilms' tumor 1-associating protein promotes renal cell carcinoma proliferation by regulating CDK2 mRNA stability.
    Tang J; Wang F; Cheng G; Si S; Sun X; Han J; Yu H; Zhang W; Lv Q; Wei JF; Yang H
    J Exp Clin Cancer Res; 2018 Feb; 37(1):40. PubMed ID: 29482572
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NDRG2 is involved in the oncogenic properties of renal cell carcinoma and its loss is a novel independent poor prognostic factor after nephrectomy.
    Liang ZL; Kang K; Yoon S; Huang SM; Lim JS; Kim JM; Lim JS; Lee HJ
    Ann Surg Oncol; 2012 Aug; 19(8):2763-72. PubMed ID: 22246425
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ubenimex inhibits cell proliferation, migration and invasion in renal cell carcinoma: the effect is autophagy-associated.
    Liu S; Xie F; Wang H; Liu Z; Liu X; Sun L; Niu Z
    Oncol Rep; 2015 Mar; 33(3):1372-80. PubMed ID: 25571917
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reduced L/B/K alkaline phosphatase gene expression in renal cell carcinoma: plausible role in tumorigenesis.
    Sharma U; Pal D; Singh SK; Kakkar N; Prasad R
    Biochimie; 2014 Sep; 104():27-35. PubMed ID: 24909115
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of MMP-9 using a pyrrole-imidazole polyamide reduces cell invasion in renal cell carcinoma.
    Sato A; Nagase H; Obinata D; Fujiwara K; Fukuda N; Soma M; Yamaguchi K; Kawata N; Takahashi S
    Int J Oncol; 2013 Nov; 43(5):1441-6. PubMed ID: 23969530
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Silencing glucose-regulated protein 78 induced renal cell carcinoma cell line G1 cell-cycle arrest and resistance to conventional chemotherapy.
    Lin JA; Fang SU; Su CL; Hsiao CJ; Chang CC; Lin YF; Cheng CW
    Urol Oncol; 2014 Jan; 32(1):29.e1-11. PubMed ID: 23428538
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.